|
Investigations of the Type II Diabetes
|
| Semaglutide mimics the hormone glucagon-like peptide 1 (GLP-1), which is produced in the gut when you eat and tells the rest of the body when you are full. Most importantly, GLP-1 receptors are found in the brain, stomach and pancreas. In the brain, GLP-1 kills food cravings, and in the stomach, GLP-1 slows down the digestive process. Importantly, in the pancreas, the presence of GLP-1 produces insulin and raises blood sugar levels by reducing glucagon production. GLP-1 abnormalities are a central component of type 2 diabetes. |
|
Re: Investigations of the Type II Diabetes
|
| Hi. I came across an interesting article on https://www.hg.org/legal-articles/why-we-expect-future-fda-investigations-of-the-type-ii-diabetes-drug-semaglutide-64494 and thought I'd share my thoughts on it. Basically, the article discusses why we may see future FDA investigations into a drug called Semaglutide, which is used to treat type II diabetes. Obviously, there have been some concerns about the potential side effects of the drug, especially when it comes to the cardiovascular system. |